MA5-13685

antibody from Invitrogen Antibodies

Targeting: TIMP1 CLGI, EPO, TIMP

Western blot

Antibody data

Submit

Validation data

Product number: MA5-13685 - Provider product page
Provider: Invitrogen Antibodies
Product name: TIMP1 Monoclonal Antibody (102D1), Biotin
Antibody type: Monoclonal
Antigen: Recombinant full-length protein
Description: MA5-13685 targets TIMP-1 in IHC (P) and WB applications and shows reactivity with Human samples. The MA5-13685 immunogen is recombinant human TIMP-1.
Reactivity: Human
Host: Mouse
Conjugate: Biotin
Isotype: IgG
Antibody clone number: 102D1
Vial size: 500 µL
Concentration: 0.2 mg/mL
Storage: 4° C

TIMP1 protein structure - MA5-13685 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Left: examples of TMAs with immunostaining for each protein. 200 x Right: ( A ) immunohistochemical staining of MMP2 in epithelial cells, ( B ) TIMP3 in epithelial cells and fibroblastic cells, ( C ) TIMP3 in inflammatory mononuclear cells, and ( D ) TIMP2 in epithelial cells, fibroblast and inflammatory mononuclear cells. 400 x .
Conjugate: Biotin

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Left: examples of tissue with immunostaining for the more significant proteins in patients with tumours belong to poor prognostic group (cluster 2 group: A , B and C ) and better prognostic group (cluster 1 group: D , E and F ; magnification x 400). ( A ) Immunohistochemical staining of matrix metalloproteinase (MMP)-11 in inflammatory mononuclear cells, tumour cells and fibroblastic cells. ( B ) Immunohistochemical staining of MMP-9 in inflammatory mononuclear cells, tumour cells and fibroblastic cell negatives. ( C ) Immunohistochemical staining of tissular inhibitors of metalloproteinase (TIMP)-1 in inflammatory mononuclear cells and in fibroblastic cells, tumour cell negatives. ( D ) No immunohistochemical staining of MMP-9 in inflammatory mononuclear cells, tumour cells and fibroblastic cells. ( E ) Immunohistochemical staining of MMP-11 in tumour cells, inflammatory mononuclear cells and fibroblastic cell negatives. ( F ) Immunohistochemical staining of TIMP-1 in fibroblastic cells, inflammatory mononuclear cells and tumour cell negatives. In all cases, inflammatory mononuclear cells are indicated with small arrows, and fibroblastic cells with large arrows.
Conjugate: Biotin

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 AlphaLISA (r) matrix metalloproteinase (MMP)-9-tissue inhibitor of metalloproteinase (TIMP)-1 interaction immunoassay for detecting recombinant MMP-9 (rMMP-9) and TIMP-1 proteins. (A) Schematic illustration of the cross-titration MMP-9-TIMP-1 template. MMP-9 and TIMP-1 concentrations from 0 to 1,000 ng/mL were used for the optimization of the technique. (B) Results of the rMMP-9-TIMP-1 interaction immunoassay expressed as binding RLU (relative luminescence units) using different concentrations of MMP-9 and TIMP-1 (0, 30, 100, 300, and 1,000 ng/mL). (C) Curve 0-1,000 ng/mL of MMP-9 with a fixed dose of 300 ng/mL TIMP-1. (D) Curve 0-1,000 ng/mL of TIMP-1 with a fixed dose of 300 ng/mL MMP-9. (C,D) assays were repeated twice. Hook point is reached at 300 ng/mL MMP-9 and 300 ng/mL TIMP-1.
Conjugate: Biotin

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5 Comparison between specific matrix metalloproteinase (MMP)-9-tissue inhibitor of metalloproteinase (TIMP)-1 interactions determined by AlphaLISA (r) immunoassay and MMP-9, TIMP-1, and MMP-9/TIMP-1 ratio levels estimated by classical ELISAs in human plasma samples from hypertensive patients with normoalbuminuria versus albuminuria. (A) AlphaLISA (r) MMP-9-TIMP-1 interaction immunoassay expressed as binding RLU (relative luminescence units) in normoalbuminuric ( n = 16) and albuminuric ( n = 20) patients. (B) Receiver-operating characteristics curve for AlphaLISA (r) MMP-9-TIMP-1 immunoassay (AUC = 0.778, 95% CI 0.63-0.93). This curve was used for comparing the ability of the AlphaLISA (r) MMP-9-TIMP-1 immunoassay to predict albuminuria in hypertensive patients. AUC, area under curve; CI, confidence interval. (C) MMP-9 and (D) TIMP-1 levels quantified by standard ELISAs. (E) MMP-9/TIMP-1 ratio estimation. * P < 0.05, ** P < 0.01, and *** P < 0.001 versus albuminuric patients. (F) Gelatinase MMP-9 activity in human plasma, upper panel, representative gelatin zymography gel, bottom panel, densitometric analysis expressed as % of change versus normoalbuminuria. In panels (A,C,D,E) , results are expressed as median values (horizontal line) and the interquartile ranges (box). In panel (F) , results are expressed in bar graph as mean values +- SEM.
Conjugate: Biotin